Details of the Drug

General Information of Drug (ID: DMAN2V2)

Drug Name

Efinopegdutide

Synonyms

MK-6024

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Peptide

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Agonist	[2]
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Non-alcoholic steatohepatitis

ICD Disease Classification

DB92.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucagon-like peptide 1 receptor (GLP1R)	DTT	GLP1R	1.25E-01	0.17	1.26
Glucagon receptor (GCGR)	DTT	GCGR	7.24E-02	-0.52	-0.92

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04944992) A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease. U.S.National Institutes of Health.
2	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.